Myriad Genetics expands partnership with Intermountain Precision Genomics, adding liquid biopsy therapy selection offering

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Myriad Genetics Inc. expanded its partnership with Intermountain Precision Genomics to add a new liquid biopsy therapy selection test to its oncology portfolio.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Results from a phase II study, led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer, and the Canadian Cancer trials Group, suggest that circulating tumor DNA analyses could be used as an early marker of immunotherapy response in advanced non-small cell lung cancer patients and may help guide therapy.

Login